Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | APC R216* |
Gene Variant Detail | |
Relevant Treatment Approaches | CTNNB1 Inhibitor Tankyrase Inhibitor |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
APC R216* | colorectal cancer | sensitive | Tankyrase Inhibitor | G007-LK | Preclinical - Cell culture | Actionable | In a preclinical study, a patient-derived colorectal cancer cell line harboring APC R216* demonstrated sensitivity to G007-LK in culture (PMID: 28179481). | 28179481 |
APC R216* | colorectal cancer | sensitive | Tankyrase Inhibitor | IWR-1 | Preclinical - Cell culture | Actionable | In a preclinical study, IWR-1 inhibited growth of a patient-derived colorectal cancer cell line harboring APC R216* in culture (PMID: 28179481). | 28179481 |
APC R216* | colorectal cancer | sensitive | Tankyrase Inhibitor | G007-LK + Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, the addition of G007-LK to Mekinist (trametinib) treatment resulted in increased inhibition of viability compared to Mekinist (trametinib) alone in a colorectal cancer patient-derived cell line harboring APC R216* in culture (PMID: 37968472). | 37968472 |